WADA publishes its 2024 List of Prohibited Substances and Methods
The World Anti-Doping Agency (WADA) has published its annual update of the List of Prohibited Substances and Methods, which will come into force on January 1, 2024.
This list, crucial for the world of sport and in particular for triathlon, establishes the substances and practices that athletes must avoid to maintain integrity and fairness in competition.
Major Updates to the 2024 List
The 2024 list brings with it important changes and additions.
Among them, the inclusion of new anabolic agents such as Trestolone y Dimethandrolone, thus expanding the category of nandrolone analogues.
In addition, adjustments have been made to the peptide hormones and growth factors section, adding substances such as Kisspeptin and its agonist analogues, which stimulate the secretion of GnRH and, therefore, the production of testosterone.
In the area of stimulants, it has been added 2-phenylpropan-1-amine (BMPEA), a substance commonly present in dietary supplements, and the list of narcotics prohibited in competition has been updated, now including Tramadol.
This latest addition responds to studies that confirm the potential of tramadol to improve physical performance, which has led to its ban in competition from 2024.
List of updates
| Category | Subcategory | Updates and Additions |
|---|---|---|
| S0. Unapproved Substances | – Inclusion of 2,4-Dinitrophenol (DNP) and troponin activators (e.g. Reldesemtiv and Tirasemtiv). | |
| S1. Anabolic Agents | – Addition of Trestolone, dimethandrolone and 11ß-methyl-19 nortestosterone as examples of nandrolone analogues. | |
| S2. Peptide Hormones, Growth Factors, Substances and Related Mimics | S2.2.1 | – Redefinition of “Testosterone-stimulating peptides in males”, including buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin. |
| S2.2.2 | – Addition of Tetracosactide (ACTH 1-24). | |
| S2.2.4 | – Inclusion of Capromorelin and ibutamoren (MK-677) as growth hormone secretagogues. | |
| S2.3 | – Added INN name for the human recombinant IGF-1 hormone, mecasermin. | |
| S4. Hormonal and Metabolic Modulators | S4.4.1 | – Update to include Rev-Erb-ɑ agonists, adding SR9011 and relocating SR9009. |
| S5. Diuretics and Masking Agents | – Editorial changes to improve clarity. Addition of Conivaptan and mozavaptan as examples of vaptan drugs. | |
| S6. Stimulants | – Addition of 2-phenylpropan-1-amine (BMPEA) and Tramazoline. | |
| S7. Narcotics | – Prohibition of Tramadol in competition from January 1, 2024. | |
| M1. Handling of Blood and Blood Components | – Donation of plasma or plasma components by plasmapheresis is no longer prohibited when performed at a registered collection center. | |
| S9. Glucocorticoids | – Salmeterol and vilanterol removed from the list. Addition of Tapentadol and dihydrocodeine to monitor usage patterns in competition. Addition of the GLP-1 analogue semaglutide to examine prevalence and pattern of use in sport. |
Check all changes
Implications for Triathletes
These updates have a direct impact on the preparation and participation of triathletes in competitions.
It is essential that athletes, coaches and medical staff are aware of these changes to avoid potential anti-doping rule violations.
There are no previous results.
